Havla J - Search Results

1

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: havla j. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765

2

Optical Coherence Tomography: Retinal Imaging Contributes to the Understanding of Brain Pathology in Classical Galactosemia.

Lotz-Havla AS, Christmann T, Parhofer KG, Maier EM, Havla J. Lotz-Havla AS, et al. Among authors: havla j. J Clin Med. 2023 Mar 3;12(5):2030. doi: 10.3390/jcm12052030. J Clin Med. 2023. PMID: 36902816 Free PMC article.

3

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants.

Wolf HN, Ehinger V, Guempelein L, Banerjee P, Kuempfel T, Havla J, Pauly D. Wolf HN, et al. Among authors: havla j. Curr Issues Mol Biol. 2023 Sep 7;45(9):7319-7335. doi: 10.3390/cimb45090463. Curr Issues Mol Biol. 2023. PMID: 37754247 Free PMC article.

4

[Progress of therapy in patients with multiple sclerosis].

Kümpfel T, Havla J, Hohlfeld R. Kümpfel T, et al. Among authors: havla j. MMW Fortschr Med. 2010 Mar 4;152(9):42-4. MMW Fortschr Med. 2010. PMID: 20384096 German. No abstract available.

5

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kümpfel T. Havla J, et al. J Neurol. 2011 Sep;258(9):1665-9. doi: 10.1007/s00415-011-5996-y. Epub 2011 Mar 23. J Neurol. 2011. PMID: 21431380

6

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T. Pellkofer HL, et al. Among authors: havla j. Neurology. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881. Neurology. 2011. PMID: 21482945

7

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Havla JB, et al. Arch Neurol. 2012 Feb;69(2):262-4. doi: 10.1001/archneurol.2011.1057. Arch Neurol. 2012. PMID: 22332194

8

[2012: Update on diagnosis and treatment of multiple sclerosis].

Havla J, Kümpfel T, Hohlfeld R. Havla J, et al. Dtsch Med Wochenschr. 2012 Apr;137(17):894-9. doi: 10.1055/s-0032-1304927. Epub 2012 Apr 10. Dtsch Med Wochenschr. 2012. PMID: 22492476 Review. German. No abstract available.

9

Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".

Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R. Havla J, et al. Mult Scler. 2013 Aug;19(9):1213-5. doi: 10.1177/1352458512466165. Epub 2012 Nov 1. Mult Scler. 2013. PMID: 23124790

10

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T. Havla J, et al. J Neurol. 2013 May;260(5):1382-7. doi: 10.1007/s00415-012-6808-8. Epub 2012 Dec 25. J Neurol. 2013. PMID: 23266894

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page